Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%
Ph phase_3
3
60%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(3)
Completed(1)
Other(1)

Detailed Status

Recruiting2
Enrolling by invitation1
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 33 (75.0%)

Trials by Status

recruiting240%
enrolling_by_invitation120%
completed120%
unknown120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_3

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141
recruitingphase_3

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

NCT06660394
enrolling_by_invitationphase_3

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

NCT06908226
unknown

Intermediate-Size Expanded Access Protocol (EAP) for LP352

NCT06149663
completedphase_1

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

NCT05364021

Clinical Trials (5)

Showing 5 of 5 trials
NCT06719141Phase 3

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

Recruiting
NCT06660394Phase 3

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Recruiting
NCT06908226Phase 3

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)

Enrolling By Invitation
NCT06149663

Intermediate-Size Expanded Access Protocol (EAP) for LP352

Unknown
NCT05364021Phase 1

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5